Literature DB >> 7303346

Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma.

D L Lamm, J A Reyna, D F Reichert.   

Abstract

Transitional cell carcinoma is known to be an immunogenic tumour. This immunogenicity has been the basis of a search for effective immunotherapeutic agents and for the evaluation in this study of two additional agents, keyhole-limpet haemacyanin (KLH) and immune ribonucleic acid (RNA) extract. The results in this animal model showed KLH to be a potent non-specific stimulant of the immune response which caused both a reduction in tumour growth and a prolongation of animal survival (p = 0.01). No anti-tumour effects were observed with either local or systemic RNA.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7303346     DOI： 10.1007/bf00256891

Source DB:  PubMed          Journal:  Urol Res        ISSN： 0300-5623


  19 in total

1.  Complete and apparently specif local tumor regression using syngeneic or xenogeneic "tumor-immune" RNA extracts.

Authors:  S I Schlager; R E Paque; S Dray
Journal:  Cancer Res       Date:  1975-08       Impact factor: 12.701

2.  Immunologic reduction of bladder cancer recurrence rate.

Authors:  C A Olsson; R Chute; C N Rao
Journal:  J Urol       Date:  1974-02       Impact factor: 7.450

3.  Cellular and humoral immune responses to human urinary bladder carcinomas.

Authors:  J Bubeník; P Perlmann; K Helmstein; G Moberger
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

4.  Anti-keyhole limpet hemocyanin antibody in normal unsensitized individuals.

Authors:  G P Burke; K A Smith; R I Stocking; M Ferm; O R McIntyre
Journal:  J Allergy Clin Immunol       Date:  1977-04       Impact factor: 10.793

5.  Levamisole immunotherapy of experimental transitional cell carcinoma.

Authors:  D L Lamm; G N Yee; D F Reichert; H M Radwin
Journal:  Invest Urol       Date:  1979-01

6.  Interspecies "transfer" of delayed hypersensitivity in vitro with RNA extracts.

Authors:  R E Paque; S Dray
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

7.  Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder.

Authors:  H W Herr; N Kemeny; A Yagoda; W F Whitmore
Journal:  Natl Cancer Inst Monogr       Date:  1978-12

8.  Levamisole in the treatment of non-invasive and invasive bladder cancer: a preliminary report.

Authors:  R B Smith; J Dekernion; B Baron; D G Skinner; J J Kaufman
Journal:  J Urol       Date:  1978-03       Impact factor: 7.450

9.  Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report.

Authors:  J A Martinez-Piñeiro; P Muntañola
Journal:  Eur Urol       Date:  1977       Impact factor: 20.096

10.  Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors.

Authors:  D L Lamm; S C Harris; R F Gittes
Journal:  Invest Urol       Date:  1977-03
View more
  4 in total

1.  Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.

Authors:  D L Lamm; J I DeHaven; D R Riggs; C Delgra; R Burrell
Journal:  Urol Res       Date:  1993-01

Review 2.  BCG in the treatment of superficial cancer of the bladder: a review.

Authors:  S Friberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

3.  Keyhole-limpet haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma.

Authors:  W G Walsh; P Tomashefsky; C A Olsson; R deVere White
Journal:  Urol Res       Date:  1983

Review 4.  Biologic response modifiers in the management of superficial bladder cancer.

Authors:  S Serels; J Fleischmann
Journal:  World J Urol       Date:  1997       Impact factor: 3.661
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.